Value-Based Formulary Principles
| Drug Category | Clinical Value | Cost-Sharing Design |
|---|---|---|
| Preventive medications (statins, antihypertensives) | High — prevents costly events | $0 cost-sharing |
| Chronic disease medications (diabetes, asthma) | High — manages costly conditions | Low cost-sharing ($5–$15) |
| Acute care medications (antibiotics) | Medium — treats acute conditions | Standard cost-sharing |
| Lifestyle medications (hair loss, ED) | Low — no clinical necessity | High cost-sharing or excluded |
| Brand drugs with generic equivalents | Low — generic is equivalent | High cost-sharing or excluded |
Adherence Impact
Cost-sharing significantly affects medication adherence. Studies show that every $10 increase in copay reduces adherence by 5–10%. For chronic disease medications — where adherence is critical for preventing costly complications — high cost-sharing is counterproductive. Value-based formularies reduce cost-sharing for high-value medications to improve adherence and reduce downstream costs.
VBID Implementation
IQ Insight
Value-based insurance design (VBID) — reducing cost-sharing for high-value services and medications — consistently improves adherence and reduces total healthcare costs. A VBID program that reduces cost-sharing for diabetes medications to $0 improves adherence by 15–20% and reduces diabetes-related hospitalizations by 10–15%. The cost of the reduced cost-sharing is far less than the savings from improved adherence.